Inotuzumab ozogamicin: Phase III final data

Final data from the open-label, international Phase III INO-VATE ALL (Study B1931022) trial in 326 patients with relapsed or refractory CD22-positive ALL showed that once-weekly 0.5-0.8 mg/m 2 IV

Read the full 297 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE